Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the German-Austrian ABSORB RegIstRy.
bioresorbable scaffold
learning curve
scaffold thrombosis
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
28
05
2021
received:
16
04
2021
accepted:
05
06
2021
pubmed:
19
6
2021
medline:
21
10
2021
entrez:
18
6
2021
Statut:
ppublish
Résumé
We aimed to investigate predictors of scaffold failure and the potential impact of an optimized scaffold implantation technique by means of a learning curve on long-term clinical outcome after bioresorbable scaffold (BRS) implantation and to evaluate predictors of scaffold failure. A total of 3326 patients were included in this prospective, observational, multi-center study (ClinicalTrials.gov NCT02066623) of consecutive patients undergoing BRS implantation between November 2013 and January 2016. The 3144 patients completed follow-up after 24 months, 3265 patients were eligible for time-to-event-analysis. Clinical endpoints were major adverse cardiac events-a composite endpoint of death, target vessel revascularization and myocardial infarction, and scaffold thrombosis (ScT). Patients were grouped according to treatment before or since 2015. During follow-up MACE rate improved from 2.52% after 30 days, 5.45% after 6 months and 12.67% after 24 months to 1.52%, 3.44%, and 10.52%, respectively. A total of 75 ScT occurred. In multiple regression analysis, treatment of bifurcations, long lesions, and procedures performed earlier than 2014 were identified as predictors for the occurrence of ScT. Treatment of bifurcation lesions is the strongest predictor of ScT following BRS implantation. A significantly lower incidence of ScT and 24-month target lesion revascularization in patients recruited after 2014 into our observational registry suggests the influence of a learning curve.
Banques de données
ClinicalTrials.gov
['NCT02066623']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E555-E563Informations de copyright
© 2021 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Roura G, Homs S, Ferreiro JL, et al. Preserved endothelial vasomotor function after everolimus-eluting stent implantation. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;11:643-649.
Costopoulos C, Naganuma T, Latib A, Colombo A. Looking into the future with bioresorbable vascular scaffolds. Expert Rev Cardiovasc Ther. 2013;11:1407-1416.
Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16-25b.
Chevalier B, Onuma Y, van Boven AJ, et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2016;12:1102-1107.
Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;10:1144-1153.
Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2014;9:1036-1041.
Ielasi A, Cortese B, Varricchio A, et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry). EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;11:157-162.
Kraak RP, Hassell ME, Grundeken MJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC single centre real world PCI registry. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;10:1160-1168.
Ishibashi Y, Nakatani S, Sotomi Y, et al. Relation between Bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8:1715-1726.
Nef H, Wiebe J, Achenbach S, et al. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R). Cardiovasc Revasc Med. 2016;17:34-37.
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801.
Xu B, Redfors B, Yang Y, et al. Impact of operator experience and volume on outcomes after left Main coronary artery percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9:2086-2093.
Barbash IM, Minha S, Gallino R, et al. Operator learning curve for transradial percutaneous coronary interventions: implications for the initiation of a transradial access program in contemporary US practice. Cardiovasc Revasc Med. 2014;15:195-199.
Schillinger W, Athanasiou T, Weicken N, et al. Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail. 2011;13:1331-1339.
Abizaid A, Ribamar Costa J Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;10:1396-1401.
Abizaid A, Costa RA, Schofer J, et al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve Novolimus-eluting Bioresorbable coronary scaffold system for the treatment of single De novo coronary lesions. JACC Cardiovasc Interv. 2016;9:565-574.
Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014;7:89-99.
Nef HM, Wiebe J, Kastner J, et al. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2017;13:1311-1318.
Wiebe J, Liebetrau C, Dorr O, et al. Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovasc Revasc Med. 2015;16:455-460.
Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv. 2014;84:37-45.
Ortega-Paz L, Capodanno D, Gori T, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2017;12:2110-2117.
Stone GW, Abizaid A, Onuma Y, et al. Effect of technique on outcomes following Bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70:2863-2874.
Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005;45:995-998.
Ahn JM, Kang SJ, Yoon SH, et al. Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies. Am J Cardiol. 2014;113:1338-1347.
Boeder NF, Weissner M, Blachutzik F, et al. Incidental finding of strut Malapposition is a predictor of late and very late thrombosis in coronary Bioresorbable scaffolds. J Clin Med. 2019;8(5):580
Adriaenssens T, Joner M, Godschalk TC, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global European effort). Circulation. 2017;136:1007-1021.
Hong SJ, Lee SY, Hong MK. Clinical implication of optical coherence tomography-based Neoatherosclerosis. J Korean Med Sci. 2017;32:1056-1061.
Witzenbichler B, Maehara A, Weisz G, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation. 2014;129:463-470.
Prati F, Romagnoli E, Burzotta F, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc Imaging. 2015;8:1297-1305.
Allahwala UK, Cockburn JA, Shaw E, Figtree GA, Hansen PS, Bhindi R. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;10:1154-1159.
Gori T, Wiebe J, Capodanno D, et al. Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2015;11:e550-556.
Bennett J, Verbeken E, Vanhaverbeke M, et al. In-vivo vascular healing following bifurcation interventions with the Absorb bioresorbable vascular scaffold. Cardiovasc Revasc Med. 2019;21(1):70-77.